Larimar Therapeutics, Inc.(LRMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LRMR Larimar Therapeutics, Inc.

Closed Good Friday 04-17 16:00:00 EDT

1.91

+0.07

+3.80%

盘后1.76

-0.14-7.61%

19:01 EDT

High1.97	Low1.86	Vol1.09M
Open1.86	D1 Closing1.84	Amplitude5.98%
Mkt Cap122.29M	Tradable Cap59.87M	Total Shares64.03M
T/O2.09M	T/O Rate3.49%	Tradable Shares31.35M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"LRMR","market":"US","secType":"STK","nameCN":"Larimar Therapeutics, Inc.","latestPrice":1.91,"timestamp":1744920000000,"preClose":1.84,"halted":0,"volume":1094996,"hourTrading":{"tag":"盘后","latestPrice":1.7601,"preClose":1.905,"latestTime":"19:01 EDT","volume":1130,"amount":2059.8,"timestamp":1744930871651},"delay":0,"floatShares":31346339,"shares":64027892,"eps":-1.315852,"marketStatus":"Closed Good Friday","change":0.07,"latestTime":"04-17 16:00:00 EDT","open":1.86,"high":1.97,"low":1.86,"amount":2089209.663156,"amplitude":0.059783,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.315852,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":1403150400000,"exchange":"NASDAQ","adjPreClose":1.84,"preHourTrading":{"tag":"盘前","latestPrice":1.95,"preClose":1.84,"latestTime":"09:28 EDT","volume":13172,"amount":25200.7402116,"timestamp":1744896480077},"postHourTrading":{"tag":"盘后","latestPrice":1.7601,"preClose":1.905,"latestTime":"19:01 EDT","volume":1130,"amount":2059.8,"timestamp":1744930871651},"volumeRatio":2.052178372603326,"impliedVol":0.3462,"impliedVolPercentile":0.0398},"requestUrl":"/m/hq/s/LRMR","defaultTab":"news","newsList":[{"id":"2522354501","title":"Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?","url":"https://stock-news.laohu8.com/highlight/detail?id=2522354501","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522354501?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 22:34","pubTimestamp":1743172464,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.Given this risk, we thought we'd take a look at whether Larimar Therapeutics  shareholders should be worried about its cash burn. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. Let's start with an examination of the business' cash, relative to its cash burn.Does Larimar Therapeutics Have A Long Cash Runway?Larimar Therapeutics' cash burn of US$71m is about 47% of its US$152m market capitalisation. That's high expenditure relative to the value of the entire company, so if it does h","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/larimar-therapeutics-nasdaq-lrmr-good-143424776.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USJW.SI","LU2210150020.SGD","QID","TSYW.SI","IE00B3QW5Z07.USD","SQQQ","BK4585","BK4139","IE00BGHQF748.EUR","BK4588","LRMR","LU2095319765.USD","IE00B64PRP62.GBP","QLD","NDAQ","IE00BKPKM429.USD","MNQmain","USAW.SI","BK4112","TQQQ","NVIW.SI","NQmain","LU2210149790.SGD",".IXIC","PSQ"],"gpt_icon":1},{"id":"2522973008","title":"Larimar Therapeutics Price Target Maintained With a $26.00/Share by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2522973008","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522973008?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 22:21","pubTimestamp":1742912460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LRMR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2025 10:21 ET (14:21 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","LRMR"],"gpt_icon":0},{"id":"2522023409","title":"Larimar Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522023409","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522023409?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 19:12","pubTimestamp":1742901120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LRMR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2025 07:12 ET (11:12 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRMR","LENZ"],"gpt_icon":0},{"id":"2522062085","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Opthea Limited Sponsored ADR (OPT) and Larimar Therapeutics (LRMR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522062085","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522062085?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 14:40","pubTimestamp":1742884807,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Opthea Limited Sponsored ADR (OPT – Research Repor...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-opthea-limited-sponsored-adr-opt-and-larimar-therapeutics-lrmr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-opthea-limited-sponsored-adr-opt-and-larimar-therapeutics-lrmr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4139","HCSG","LRMR","OPT","CKDXF"],"gpt_icon":0},{"id":"2522770395","title":"William Blair Sticks to Their Buy Rating for Larimar Therapeutics (LRMR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522770395","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522770395?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 01:25","pubTimestamp":1742837126,"startTime":"0","endTime":"0","summary":"William Blair analyst Myles Minter maintained a Buy rating on Larimar Therapeutics (LRMR – Research Report) today. The company’s shares opened toda...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/william-blair-sticks-to-their-buy-rating-for-larimar-therapeutics-lrmr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/william-blair-sticks-to-their-buy-rating-for-larimar-therapeutics-lrmr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LRMR"],"gpt_icon":0},{"id":"2521775720","title":"Wedbush Cuts Price Target on Larimar Therapeutics to $17 From $22, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2521775720","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521775720?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 23:02","pubTimestamp":1742828527,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics (LRMR) has an average rating of buy and mean price target of $20.20, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","LRMR"],"gpt_icon":0},{"id":"2521725304","title":"Larimar Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2521725304","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521725304?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 20:50","pubTimestamp":1742820649,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryLarimar Therapeutics Inc LRMR.OQ reported a quarterly adjusted loss of 45 cents per share for the quarter e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nL5N3Q7103:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRMR"],"gpt_icon":1},{"id":"2521741934","title":"Larimar Therapeutics Q4 2024 GAAP EPS $(0.45) Misses $(0.32) Estimate, Cash $183.5M","url":"https://stock-news.laohu8.com/highlight/detail?id=2521741934","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521741934?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 19:24","pubTimestamp":1742815495,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.32) by 40.63 percent. This is a 50 percent decrease over losses of $(0.30) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44455011/larimar-therapeutics-q4-2024-gaap-eps-0-45-misses-0-32-estimate-cash-183-5m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRMR","LENZ"],"gpt_icon":0},{"id":"2521746556","title":"BRIEF-Larimar Therapeutics Q4 Net Income USD -28.824 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2521746556","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521746556?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 19:00","pubTimestamp":1742814046,"startTime":"0","endTime":"0","summary":"BRIEF-Larimar Therapeutics Q4 Net Income USD -28.824 Million\n\n\nMar 24 (Reuters) - Larimar Therapeutics Q4 operating expenses USD 31.293 million.\n\nQ4 basic EPS USD -0.45\nQ4 income from operations USD -31.293 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nPLX32C68E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRMR","BK4139"],"gpt_icon":0},{"id":"2521456627","title":"Larimar Therapeutics Q4 Basic EPS USD -0.45","url":"https://stock-news.laohu8.com/highlight/detail?id=2521456627","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521456627?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 19:00","pubTimestamp":1742814001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nPLX32C68E:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LRMR","BK4139"],"gpt_icon":0},{"id":"2521469997","title":"Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2521469997","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521469997?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 19:00","pubTimestamp":1742814000,"startTime":"0","endTime":"0","summary":"FDA stated in written correspondence for a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approval. FDA recommended measuring skin FXN concentrations to support evidence of effectiveness for accelerated approval pathway and acknowledged submitted data appear sufficient to support relationship between increased skin FXN concentrations and relevant tissues such as heart, dorsal root ganglia and skeletal muscle. Larimar is continuing discussions with FDA on the adequacy of the safety data set to support BLA submission. BLA seeking accelerated approval targeted for submission by year-end 2025. FDA and EMA feedback obtained on global Phase 3 study protocol; study planned to initiate in mid-2025. Dr. Ben-Maimon continued, “Our open label extension  study continues to advance, with some participants on daily treatment for up to one year. We continue to actively enroll study participants, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/larimar-therapeutics-provides-nomlabofusp-development-110000420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","LENZ","BK4139","BK4130","LRMR","BK4535","PK","BK4181","FXN","FA","BK4218"],"gpt_icon":0},{"id":"2519796877","title":"Larimar Therapeutics Inc  expected to post a loss of 32 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2519796877","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519796877?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 19:22","pubTimestamp":1741951328,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics Inc  expected to post a loss of32cents a share - Earnings Preview Larimar Therapeutics Inc LRMR.OQ LRMR.O is expected to show no change in quarterly revenue when it reports  resul","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250314:nL8N3PX0UL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRMR"],"gpt_icon":1},{"id":"2518471593","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2518471593","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518471593?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 18:00","pubTimestamp":1741687200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Allbirds Inc. Class A                           4Q       4:05 PM. ·Dick's Sporting Gds                              4Q      3.52   7:00 AM. ·E. W. Scripps Co                                 4Q      1.01       AMC. ·European Wax Ctr                                4Q       .06   6:00 AM. ·First Watch Rest                                4Q       .01   7:00 AM. ·Kanzhun Ltd. Sp ADR                               4Q       .22       BMO","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SID","KFY","WSM","BZ","SMSI","AGEN","AKBA","S","EBR","BIRD","KRMD","BW","DKS","LRMR","ONDS","BWAY","KALV","VTS","BTMD","SKIN","SKYX","UNFI","ZYXI","APYX","BLDE","KSS","DRUG","ABM","LEGN","ASRT","ACHV","PHLT","TH","HLLY","AFCG","QRHC","EWCZ","BBCP","WEST","MNTK","FTCI","NOA","MGTX","EXK","SSP","ATLC","SPRB","RMBL","ARCO"],"gpt_icon":1},{"id":"2517859394","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2517859394","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517859394?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 19:00","pubTimestamp":1741345200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Algonquin Pwr & Utl                              4Q       .09       BMO. ·Asana Inc. Class A                              4Q      (.01)  4:05 PM. ·Auna S.A. Class A                               4Q       .15       AMC. ·Vail Resorts Inc.                                2Q      6.29   4:05 PM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SSP","AUNA","TBRG","BDTX","VTS","EVEX","MGTX","ATLC","DRRX","KRMD","URGN","WEST","DKS","ACET","ARCO","LRMR","MYPS","MOMO","CDTX","LE","BWMN","CING","LEN.B","LMB","ORCL","HLLY","KALV","ZVRA","AMRN","BTMD","ADBE","AEO","BW","AURA","NKTR","CHRS","SFIX","CIEN","BNTX","FERG","EWCZ","GECC","DRUG","NOA","CINT","CVGW","BBCP","ASRT","FTCI"],"gpt_icon":1},{"id":"2512748589","title":"Larimar Therapeutics (LRMR) Gets a Buy from JMP Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2512748589","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512748589?lang=en_us&edition=full_marsco","pubTime":"2025-02-19 22:55","pubTimestamp":1739976909,"startTime":"0","endTime":"0","summary":"In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Larimar Therapeutics (LRMR – Research Report), with a ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/larimar-therapeutics-lrmr-gets-a-buy-from-jmp-securities-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/larimar-therapeutics-lrmr-gets-a-buy-from-jmp-securities-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","LRMR","BK4139","JMP"],"gpt_icon":0},{"id":"2510303337","title":"Insiders Re-Evaluate Their US$522.0k Stock Purchase As Larimar Therapeutics Falls To US$215m","url":"https://stock-news.laohu8.com/highlight/detail?id=2510303337","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510303337?lang=en_us&edition=full_marsco","pubTime":"2025-02-12 18:58","pubTimestamp":1739357883,"startTime":"0","endTime":"0","summary":"The recent 14% drop in Larimar Therapeutics, Inc.'s ( NASDAQ:LRMR ) stock could come as a blow to insiders who...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lrmr/larimar-therapeutics/news/insiders-re-evaluate-their-us5220k-stock-purchase-as-larimar","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LENZ","LRMR","BK4139"],"gpt_icon":0},{"id":"2507824386","title":"Larimar Therapeutics Inc : Truist Securities Initiates Coverage With Buy Rating; Target Price $18","url":"https://stock-news.laohu8.com/highlight/detail?id=2507824386","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507824386?lang=en_us&edition=full_marsco","pubTime":"2025-01-29 19:58","pubTimestamp":1738151925,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250129:nFWN3OP0VV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LRMR","BK4139"],"gpt_icon":0},{"id":"2507886682","title":"Truist sees ‘significant upside’ for Larimar Therapeutics, starts with a Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2507886682","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507886682?lang=en_us&edition=full_marsco","pubTime":"2025-01-29 19:40","pubTimestamp":1738150852,"startTime":"0","endTime":"0","summary":"As previously reported, Truist initiated coverage of Larimar Therapeutics (LRMR) with a Buy rating and $18 price target Despite “promising” preclin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/truist-sees-significant-upside-for-larimar-therapeutics-starts-with-a-buy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/truist-sees-significant-upside-for-larimar-therapeutics-starts-with-a-buy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","LRMR"],"gpt_icon":0},{"id":"2507791681","title":"Truist Initiates Larimar Therapeutics at Buy With $18 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2507791681","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507791681?lang=en_us&edition=full_marsco","pubTime":"2025-01-29 19:21","pubTimestamp":1738149678,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics (LRMR) has an average rating of buy and mean price target of $20.40, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LRMR","LENZ"],"gpt_icon":0},{"id":"2507684868","title":"Larimar Therapeutics initiated with a Buy at Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2507684868","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507684868?lang=en_us&edition=full_marsco","pubTime":"2025-01-29 19:20","pubTimestamp":1738149643,"startTime":"0","endTime":"0","summary":"Truist analyst Joon Lee initiated coverage of Larimar Therapeutics (LRMR) with a Buy rating and $18 price target Published first on TheFly – the ul...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-initiated-with-a-buy-at-truist?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-initiated-with-a-buy-at-truist?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LRMR","LENZ","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.larimartx.com","stockEarnings":[{"period":"1week","weight":0.073},{"period":"1month","weight":-0.1941},{"period":"3month","weight":-0.4281},{"period":"6month","weight":-0.7539},{"period":"1year","weight":-0.7291},{"period":"ytd","weight":-0.5065}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.102481},{"month":2,"riseRate":0.545455,"avgChangeRate":0.052852},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.145103},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.059546},{"month":5,"riseRate":0.5,"avgChangeRate":-0.086037},{"month":6,"riseRate":0.5,"avgChangeRate":-0.021475},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.041896},{"month":8,"riseRate":0.454545,"avgChangeRate":0.084567},{"month":9,"riseRate":0.454545,"avgChangeRate":0.010818},{"month":10,"riseRate":0.636364,"avgChangeRate":-0.050678},{"month":11,"riseRate":0.636364,"avgChangeRate":0.050102},{"month":12,"riseRate":0.545455,"avgChangeRate":0.048319}],"exchange":"NASDAQ","name":"Larimar Therapeutics, Inc.","nameEN":"Larimar Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Larimar Therapeutics, Inc.(LRMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Larimar Therapeutics, Inc.(LRMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Larimar Therapeutics, Inc.,LRMR,Larimar Therapeutics, Inc.股票,Larimar Therapeutics, Inc.股票老虎,Larimar Therapeutics, Inc.股票老虎国际,Larimar Therapeutics, Inc.行情,Larimar Therapeutics, Inc.股票行情,Larimar Therapeutics, Inc.股价,Larimar Therapeutics, Inc.股市,Larimar Therapeutics, Inc.股票价格,Larimar Therapeutics, Inc.股票交易,Larimar Therapeutics, Inc.股票购买,Larimar Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Larimar Therapeutics, Inc.(LRMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Larimar Therapeutics, Inc.(LRMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}